Genmab A/S (CO:GMAB) — Market Cap & Net Worth
Market Cap & Net Worth: Genmab A/S (GMAB)
Genmab A/S (CO:GMAB) has a market capitalization of $15.36 Billion (Dkr98.19 Billion) as of June 16, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #1611 globally and #8 in its home market, demonstrating a 0.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genmab A/S's stock price Dkr1594.00 by its total outstanding shares 61599307 (61.60 Million). Review how much debt does Genmab A/S carry to assess the company's total debt and financial obligations.
Genmab A/S Market Cap History: 2015 to 2026
Genmab A/S's market capitalization history from 2015 to 2026. Data shows growth from $8.84 Billion to $15.36 Billion (9.02% CAGR).
Index Memberships
Genmab A/S is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.18 Trillion | 0.21% | #95 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.18 Trillion | 0.21% | #95 of 182 |
Weight: Genmab A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genmab A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genmab A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.67x
Genmab A/S's market cap is 0.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.83x
Genmab A/S's market cap is 1.83 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $8.84 Billion | $1.13 Billion | $763.51 Million | 7.80x | 11.58x |
| 2016 | $11.30 Billion | $1.82 Billion | $1.19 Billion | 6.22x | 9.52x |
| 2017 | $9.92 Billion | $2.37 Billion | $1.10 Billion | 4.19x | 8.99x |
| 2018 | $10.29 Billion | $3.03 Billion | $1.47 Billion | 3.40x | 6.99x |
| 2019 | $14.28 Billion | $5.37 Billion | $2.17 Billion | 2.66x | 6.59x |
| 2020 | $23.74 Billion | $10.11 Billion | $4.76 Billion | 2.35x | 4.99x |
| 2021 | $25.35 Billion | $8.48 Billion | $2.96 Billion | 2.99x | 8.57x |
| 2022 | $28.34 Billion | $14.60 Billion | $5.45 Billion | 1.94x | 5.20x |
| 2023 | $20.77 Billion | $16.47 Billion | $4.35 Billion | 1.26x | 4.77x |
| 2024 | $14.38 Billion | $21.53 Billion | $7.84 Billion | 0.67x | 1.83x |
Competitor Companies of GMAB by Market Capitalization
Companies near Genmab A/S in the global market cap rankings as of June 16, 2026.
Key companies related to Genmab A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Genmab A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, Genmab A/S's market cap moved from $8.84 Billion to $ 15.36 Billion, with a yearly change of 9.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr15.36 Billion | -21.36% |
| 2025 | Dkr19.54 Billion | +35.81% |
| 2024 | Dkr14.38 Billion | -30.74% |
| 2023 | Dkr20.77 Billion | -26.73% |
| 2022 | Dkr28.34 Billion | +11.83% |
| 2021 | Dkr25.35 Billion | +6.78% |
| 2020 | Dkr23.74 Billion | +66.25% |
| 2019 | Dkr14.28 Billion | +38.78% |
| 2018 | Dkr10.29 Billion | +3.74% |
| 2017 | Dkr9.92 Billion | -12.28% |
| 2016 | Dkr11.30 Billion | +27.85% |
| 2015 | Dkr8.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Genmab A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.36 Billion USD |
| MoneyControl | $15.36 Billion USD |
| MarketWatch | $15.36 Billion USD |
| marketcap.company | $15.36 Billion USD |
| Reuters | $15.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more